Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1 (ARIH2P1) is classified as a pseudogene, meaning it is a nonfunctional segment of DNA that resembles its parent gene (ARIH2, which encodes a ubiquitin ligase protein), but ARIH2P1 itself does not encode a functional protein due to disabling mutations[1][3][5]. Pseudogenes like ARIH2P1 may be transcribed into non-coding RNAs and, in rare cases, participate in gene regulation (such as acting as microRNA decoys or generating regulatory RNAs), but no evidence is available that ARIH2P1 itself has such functions[2][5]. It is not considered a therapeutic target, does not interact with drugs, and has no known relevance as a disease biomarker or safety concern. Pseudogenes can occasionally complicate genetic studies due to sequence similarity with their functional counterparts[5].
None known (Not a druggable protein, not targeted by small molecules or biologics)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1 (ARIH2P1).